Molecular structure of Aminopurvalanol A, CAS Number: 220792-57-4
Aminopurvalanol A (CAS 220792-57-4)
Alternate Names:
(2R)-2-((6-((3-Amino-5-chlorophenyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-3-methyl-1-butanol; NG-97
Application:
Aminopurvalanol A is a reversible and ATP-competitive inhibitor of Cdks
CAS Number:
220792-57-4
Molecular Weight:
403.91
Molecular Formula:
C19H26ClN7O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Aminopurvalanol A is a cell-permeable 2,6,9-trisubstituted purine analog that displays anti-mitotic as well as anti-tumor properties (GI50 ~ 1.8 muM in the NCI 60-cell panel in vitro activity screen potently inhibits the growth of KM12 colon cancer cells with a GI50 of 30 nM) Aminopurvalanol A acts as a reversible and ATP-competitive inhibitor of Cdks (IC50 = 33 nM for cdc2 (Cdk1)/cyclin B and Cdk2/cyclin A, 28 nM for Cdk2/cyclin E, and 20 nM for Cdk5/p35), and displays ~ 100-fold greater selectivity over a panel of kinases tested (IC50 ≥ 2.4 muM). Aminopurvalanol A may act to induce cell differentiation by preferentially targeting the G2/M-phase and act intracellularly by inhibiting both Cdks and MAPKs.
Aminopurvalanol A (CAS 220792-57-4) References
- Cyclin-dependent kinase 5 is involved in the phosphorylation of gephyrin and clustering of GABAA receptors at inhibitory synapses of hippocampal neurons. | Kalbouneh, H., et al. 2014. PLoS One. 9: e104256. PMID: 25093719
- A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. | Shi, Y., et al. 2017. Bioorg Med Chem Lett. 27: 406-412. PMID: 28049589
- Aminopurvalanol A, a Potent, Selective, and Cell Permeable Inhibitor of Cyclins/Cdk Complexes, Causes the Reduction of in Vitro Fertilizing Ability of Boar Spermatozoa, by Negatively Affecting the Capacitation-Dependent Actin Polymerization. | Bernabò, N., et al. 2017. Front Physiol. 8: 1097. PMID: 29312003
- Target RNA modification for epigenetic drug repositioning in neuroblastoma: computational omics proximity between repurposing drug and disease. | Ma, P., et al. 2020. Aging (Albany NY). 12: 19022-19044. PMID: 33044945
- Immune Infiltration, Cancer Stemness, and Targeted Therapy in Gastrointestinal Stromal Tumor. | Wang, J., et al. 2021. Front Immunol. 12: 691713. PMID: 34925310
- Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential Compounds. | Mai, H., et al. 2022. Cancers (Basel). 14: PMID: 35158838
- Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment. | Murphy, AJ., et al. 2022. Front Oncol. 12: 868664. PMID: 35463320
- Comprehensive Analysis of Endoplasmic Reticulum Stress in Intracranial Aneurysm. | Chen, B., et al. 2022. Front Cell Neurosci. 16: 865005. PMID: 35465608
- Comprehensive analysis of histone methylation modification regulators for predicting prognosis and drug sensitivity in lung adenocarcinoma. | Ye, Y., et al. 2022. Front Cell Dev Biol. 10: 991980. PMID: 36263018
- Construction of a prognostic model based on eight ubiquitination-related genes via machine learning and potential therapeutics analysis for cervical cancer. | Hao, Y., et al. 2023. Front Genet. 14: 1142938. PMID: 36999051
- SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. | Walters, R., et al. 2023. Circulation. 147: 1606-1621. PMID: 37066790
- EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates. | Fan, K., et al. 2023. BMC Bioinformatics. 24: 149. PMID: 37069494
- Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer. | Zhang, J., et al. 2023. Front Oncol. 13: 1162653. PMID: 37205181
Inhibitor of:
Cdc2, Cdk2, Cdk5, cyclin A, cyclin B, cyclin E, and p35.Activator of:
IgM.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aminopurvalanol A, 1 mg | sc-223775 | 1 mg | $51.00 | |||
Aminopurvalanol A, 5 mg | sc-223775A | 5 mg | $118.00 |